Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

BACKGROUND: As treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated with fast...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cost Eff Resour Alloc
Autors principals: McEwan, Phil, Webster, Samantha, Ward, Thomas, Brenner, Michael, Kalsekar, Anupama, Yuan, Yong
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5521139/
https://ncbi.nlm.nih.gov/pubmed/28736505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-017-0077-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars